Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Shanghai - Delayed Quote CNY

Changchun BCHT Biotechnology Co. (688276.SS)

20.29
-0.56
(-2.69%)
At close: 3:00:03 PM GMT+8
Loading Chart for 688276.SS
  • Previous Close 20.85
  • Open 20.72
  • Bid 20.28 x --
  • Ask 20.29 x --
  • Day's Range 20.28 - 20.73
  • 52 Week Range 20.19 - 41.78
  • Volume 2,034,618
  • Avg. Volume 2,944,706
  • Market Cap (intraday) 8.393B
  • Beta (5Y Monthly) -0.01
  • PE Ratio (TTM) 49.49
  • EPS (TTM) 0.41
  • Earnings Date --
  • Forward Dividend & Yield 0.15 (0.69%)
  • Ex-Dividend Date May 24, 2024
  • 1y Target Est --

Changchun BCHT Biotechnology Co. Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of human vaccines in China and internationally. The company's products include live herpes zoster vaccine; live varicella vaccine; live, nasal, and freeze-dried influenza vaccine; and Rabies vaccine (vero cell) for humans. Changchun BCHT Biotechnology Co. Ltd. was founded in 2004 and is based in Changchun, China.

www.bchtpharm.com

1,241

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 688276.SS

View More

Performance Overview: 688276.SS

Trailing total returns as of 4/28/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

688276.SS
19.20%
SSE Composite Index (000001.SS)
1.89%

1-Year Return

688276.SS
47.15%
SSE Composite Index (000001.SS)
6.47%

3-Year Return

688276.SS
43.89%
SSE Composite Index (000001.SS)
10.52%

5-Year Return

688276.SS
83.09%
SSE Composite Index (000001.SS)
17.02%

Compare To: 688276.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 688276.SS

View More

Valuation Measures

Annual
As of 4/25/2025
  • Market Cap

    8.62B

  • Enterprise Value

    8.58B

  • Trailing P/E

    50.85

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    7.69

  • Price/Book (mrq)

    2.05

  • Enterprise Value/Revenue

    7.65

  • Enterprise Value/EBITDA

    45.20

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    25.77%

  • Return on Assets (ttm)

    5.57%

  • Return on Equity (ttm)

    10.29%

  • Revenue (ttm)

    1.61B

  • Net Income Avi to Common (ttm)

    414.29M

  • Diluted EPS (ttm)

    0.41

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    277.89M

  • Total Debt/Equity (mrq)

    1.49%

  • Levered Free Cash Flow (ttm)

    -303.72M

Research Analysis: 688276.SS

View More

Company Insights: 688276.SS

Research Reports: 688276.SS

View More

People Also Watch